![Robert Alonso](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Robert Alonso
Directeur/Bestuurslid bij MEDESIS PHARMA S.A.
Momenteel actieve connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
Jean-Claude Maurel | M | - | 21 jaar | |
Linda P. Dwoskin | F | - |
Ceptaris Therapeutics, Inc.
![]() Ceptaris Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ceptaris Therapeutics, Inc. develops mechlorethamine gels. The firm develops a gel formulation of mechlorethamine hydrochloride for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma. The company was founded in 2002 and is headquartered in Malvern, PA. | 22 jaar |
John G. Geisler | M | - |
Mitochon Pharmaceuticals, Inc.
![]() Mitochon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Mitochon Pharmaceuticals, Inc. operates as a biotech company. It focuses on developing drugs that target the mitochondria for a host of serious diseases. The firm provides products to resolve the over-nutritional phenotype metabolic disorders. The company was founded by Robert Alonso and John G. Geisler in 2014 and is headquartered in Blue Bell, PA. | 10 jaar |
Olivier Connes | M | - | 6 jaar | |
Bernard Connes-Lafforet | M | - | 5 jaar | |
Walt Linscott | M | 63 | 2 jaar | |
Mario Alcaraz | M | - | - | |
Jean-Marie Cazaledes | M | - | 9 jaar | |
Cédric Navas | M | - | 6 jaar | |
Emmanuel Hebert | M | - | 5 jaar | |
Jean-Philippe Causse | M | - | 3 jaar | |
Solene Guilliot | M | - | 3 jaar |
Relatiegrafiek
Connectie in verschillende bedrijven
Oude connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
Stephen Tullman | M | 58 |
Ceptaris Therapeutics, Inc.
![]() Ceptaris Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ceptaris Therapeutics, Inc. develops mechlorethamine gels. The firm develops a gel formulation of mechlorethamine hydrochloride for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma. The company was founded in 2002 and is headquartered in Malvern, PA. | 2 jaar |
Kamil Ali-Jackson | F | 65 |
Ceptaris Therapeutics, Inc.
![]() Ceptaris Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ceptaris Therapeutics, Inc. develops mechlorethamine gels. The firm develops a gel formulation of mechlorethamine hydrochloride for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma. The company was founded in 2002 and is headquartered in Malvern, PA. | 2 jaar |
Peter Crooks | M | - |
Ceptaris Therapeutics, Inc.
![]() Ceptaris Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ceptaris Therapeutics, Inc. develops mechlorethamine gels. The firm develops a gel formulation of mechlorethamine hydrochloride for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma. The company was founded in 2002 and is headquartered in Malvern, PA. | - |
H. Wilkins | M | 62 |
Ceptaris Therapeutics, Inc.
![]() Ceptaris Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ceptaris Therapeutics, Inc. develops mechlorethamine gels. The firm develops a gel formulation of mechlorethamine hydrochloride for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma. The company was founded in 2002 and is headquartered in Malvern, PA. | 3 jaar |
Statistieken
Land | Connecties | % van het totaal |
---|---|---|
Frankrijk | 10 | 62.50% |
Verenigde Staten | 6 | 37.50% |
Ouderdom van de connecties
Actief
Verleden
Man
Vrouw
Besturend
Uitvoerend
Oorsprong van de connecties
- Beurs
- Insiders
- Robert Alonso
- Persoonlijk netwerk